Due: 2024-01 Development and validation of wearable device derived objective biosignatures or functional assessments

DUE: January 30, 2024

To enable the development and validation of real-world remote digital endpoints from wearable devices for monitoring pain experience and progression, response to interventions, and impact on quality of life. In the context of this RFA, endpoints will include biosignatures derived from functional and physiological assessments detected from wearable devices. These biosignatures can be used to monitor the effects of therapeutics developed for the treatment of pain.